Literature DB >> 23944372

An epidemiological study of neovascular age-related macular degeneration in Germany.

Lothar Krause1, Tarik Yousif, Karin Pohl.   

Abstract

OBJECTIVE: Neovascular or wet age-related macular degeneration (AMD) is one of the leading causes of blindness in industrialized countries; however, there is a lack of recent epidemiological data from Germany. The aim of this study was to collect epidemiological data from patients in Germany with suspected neovascular AMD and evaluate the diagnostic procedures performed and treatments used at clinics.
METHODS: This was a Germany-based, multicentre, retrospective review of data from patients with suspected neovascular AMD visiting ophthalmology clinics over an 18 month period in 2008-10. Clinical characteristics, functional symptoms and examination results were recorded. In addition, ophthalmologists completed a questionnaire on neovascular AMD diagnosis and treatment.
RESULTS: Ten sites collected data from 2498 patients (64.0% female) with a mean decimal visual acuity of 0.4 ± 0.3 at the time of diagnosis of neovascular AMD. The mean age at the time of diagnosis was 76.9 ± 8.9 years for patients with the right eye affected and 77.0 ± 8.3 years for patients with the left eye affected. The most frequent pathological findings detected by routine ophthalmic examination were old lesions (31.2%), intra/subretinal fluid (18.1%), new lesions (13.0%), and intra/subretinal haemorrhage (11.4%). A confirmed diagnosis of neovascular AMD was most frequently based on fundoscopy (67.3%), fluorescein angiography (39.6%), and biomicroscopy (35.7%) tests but rarely on optical coherence tomography (8.9%). The most frequently documented comorbidity with neovascular AMD was hypertension and other cardiovascular diseases (57.5%). Seven ophthalmologists completed the questionnaire with the majority of ophthalmologists agreeing that regular ophthalmic examination can prevent the development of late-stage neovascular AMD.
CONCLUSION: Neovascular AMD is a frequent diagnosis in German ophthalmology clinics. As visual acuity is already poor in most patients with suspected neovascular AMD, regular preventive ophthalmologic examinations should be considered in high risk patients. STUDY LIMITATIONS: Limitations of the study include the lack of a comparator cohort, which limited the amount of analyses that could be performed. Additionally, a study eye was not defined and information was collected separately for each affected eye and therefore analysed separately. Furthermore, a small number of ophthalmologists completed the questionnaire, limiting the objectivity.

Entities:  

Mesh:

Year:  2013        PMID: 23944372     DOI: 10.1185/03007995.2013.832184

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  5 in total

Review 1.  Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA).

Authors:  Ursula Schmidt-Erfurth; Victor Chong; Anat Loewenstein; Michael Larsen; Eric Souied; Reinier Schlingemann; Bora Eldem; Jordi Monés; Gisbert Richard; Francesco Bandello
Journal:  Br J Ophthalmol       Date:  2014-09       Impact factor: 4.638

Review 2.  Management of neovascular age-related macular degeneration: current state-of-the-art care for optimizing visual outcomes and therapies in development.

Authors:  Aniruddha Agarwal; William R Rhoades; Mostafa Hanout; Mohamed Kamel Soliman; Salman Sarwar; Mohammad Ali Sadiq; Yasir Jamal Sepah; Diana V Do; Quan Dong Nguyen
Journal:  Clin Ophthalmol       Date:  2015-06-05

Review 3.  Bringing the age-related macular degeneration high-risk allele age-related maculopathy susceptibility 2 into focus with stem cell technology.

Authors:  Shuo Sun; ZhiQing Li; Patrick Glencer; BinCui Cai; XiaoMin Zhang; Jin Yang; XiaoRong Li
Journal:  Stem Cell Res Ther       Date:  2017-06-06       Impact factor: 6.832

4.  Demographics of patients receiving Intravitreal anti-VEGF treatment in real-world practice: healthcare research data versus randomized controlled trials.

Authors:  F Ziemssen; N Feltgen; F G Holz; R Guthoff; A Ringwald; T Bertelmann; A Wiedon; C Korb
Journal:  BMC Ophthalmol       Date:  2017-01-19       Impact factor: 2.209

5.  ORCA study: real-world versus reading centre assessment of disease activity of neovascular age-related macular degeneration (nAMD).

Authors:  Sandra Liakopoulos; Georg Spital; Christian K Brinkmann; Tina Schick; Focke Ziemssen; Jessica Voegeler; Mirja Koch; Bernd Kirchhof; Frank G Holz; Daniel Pauleikhoff; Steffen Schmitz-Valckenberg
Journal:  Br J Ophthalmol       Date:  2020-02-17       Impact factor: 4.638

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.